KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCvaccines Revenue BreakdownDeferred RevenueEbt By SegmentEbt Margin By Segment %Employee StatisticsGross Margin %Gross ProfitGross Profit AnnualGross Profit Annual %Hospital Revenue BreakdownIncome Before Income TaxInflammation And Immunology Revenue BreakdownInternal Medicine Revenue BreakdownInventoriesLong Lived Assets By RegionNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Oncology Revenue BreakdownOperating Costs & ExpensesOpex & Costs As A % Of RevenueProperty, Plant And Equipment SegregationRare Disease Revenue BreakdownRemaining Performance ObligationsRemaining Performance Obligations AnnualRevenue By Business VerticalRevenue By Business Vertical %Revenue By Business Vertical Annual %Revenue By Customer GroupRevenue By Customer Group %Revenue By Products AnnualaRevenue By Products Annuala %Revenue By RegionRevenue By Region %Revenue By Region AnnualRevenue By Region Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Revenue By Therapeutic Area AnnualRevenue By Therapeutic Area Annual %Revenue By WholesalersRevenue By Wholesalers %U.S Revenue By Wholesalers %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Gross Profit (2016 - 2025)

Historic Gross Profit for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $12.5 billion.

  • Pfizer's Gross Profit rose 34.57% to $12.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $46.7 billion, marking a year-over-year increase of 5663.41%. This contributed to the annual value of $45.8 billion for FY2024, which is 3230.44% up from last year.
  • As of Q3 2025, Pfizer's Gross Profit stood at $12.5 billion, which was up 34.57% from $10.9 billion recorded in Q2 2025.
  • Pfizer's Gross Profit's 5-year high stood at $19.1 billion during Q3 2022, with a 5-year trough of -$4.1 billion in Q4 2023.
  • For the 5-year period, Pfizer's Gross Profit averaged around $9.7 billion, with its median value being $11.2 billion (2024).
  • As far as peak fluctuations go, Pfizer's Gross Profit tumbled by 10803.09% in 2023, and later skyrocketed by 384584.98% in 2024.
  • Quarter analysis of 5 years shows Pfizer's Gross Profit stood at $14.1 billion in 2021, then increased by 17.53% to $16.6 billion in 2022, then tumbled by 124.91% to -$4.1 billion in 2023, then surged by 401.26% to $12.4 billion in 2024, then grew by 0.35% to $12.5 billion in 2025.
  • Its Gross Profit stands at $12.5 billion for Q3 2025, versus $10.9 billion for Q2 2025 and $10.9 billion for Q1 2025.